RecruitingChronic Lymphocytic LeukemiaHematopoietic and Lymphoid System NeoplasmMantle Cell Lymphoma
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Eligible age
All ages
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.
Sponsor: Mayo Clinic
You may qualify if…
- ✓ Patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), and marginal zone lymphoma (MZL), planned to begin Bruton tyrosine kinase inhibitors (BTKi) treatment or who will start a new BTKi agent after a 5-day wash out period (either as a single agent or on combination with other chemotherapies), who are willing to return to Mayo Clinic for ongoing follow-up
You may not qualify if…
- ✕ Patients with known central nervous system (CNS) involvement of their B-cell malignancy
Where it's recruiting
Minnesota
Rochester
Source: ClinicalTrials.gov · NCT06151730 · last updated 2026-02-27